PDCD1 and neoplasm: In this study, we aimed to explore the role of plasma and tissue EBV biomarkers, including plasma EBV DNA load, tumor neoantigen burden (TNB), lytic EBV genes and EBV strains, for predicting RM-NPC patients’ response to anti-PD-1 monotherapy by analyzing the data from two phase I clinical trials evaluating camrelizumab and nivolumab.